MMMarwan Mahtook

Marwan Mahtook

*This is an algorithmically generated author record based on publicly available information.

Marwan Mahtook has a total of 4 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Real-world data on the effectiveness of the meloxicam and pridinol combination for musculoskeletal pain

    by Marwan Mahtook, Maiss Saadi, Saifan Alhameedawi, Noor M. Obaid, Khulood Alsaraf

    Musculoskeletal pain includes several types of discomfort associated with the skeletal system. Pharmaceutically, pridinol was developed in order to relax muscles. No empirical data exist to support the effectiveness of using meloxicam in combination therapy for the treatment of musculoskeletal pain. This study compared pridinol and meloxicam for musculoskeletal pain. The current observational study assessed a total of 82 patients. The study’s participants were divided into three groups: the “meloxicam” group, the “pridinol” group, and the “meloxicam + pridinol” group. Pain levels were measured before and four weeks after giving the drug, by using a visual analogue scale (VAS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). We employed a Kruskal-Wallis test in order to evaluate the variations in pain measurement among the groups. The three groups’ VAS and WOMAC scores did not differ before the drug administration. The “meloxicam + pridinol” treatment resulted in significant pain relief based on VAS and WOMAC scores at 1, 2, and 4 weeks (as compared to other groups; p<0.05). At 4 weeks, the VAS and WOMAC ratings exhibited no significant pain relief in the “meloxicam” group when compared to the “pridinol” group. The meloxicam-pridinol combination proved efficacious for musculoskeletal pain, and is recom¬mended for its therapy.